Johnson Johnson Aktie

166,40 EUR +1,12 EUR +0,68 %

12:38:16

XETRA

193,23 USD -0,01 USD -0,01 %

vorbörslich13:22:50

BTT

Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.401,47 Mrd. EUR

KGV24,98Div. Rendite3,40%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

Sortieren:Datum Meistgelesen

20.10.25EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy

19.10.25EN, Johnson & JohnsonSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

19.10.25PR NewswireSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

WerbungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.10.25PR NewswireTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

16.10.25EN, Johnson & JohnsonTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

15.10.25EN, Johnson & JohnsonJohnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types

14.10.25EN, Johnson & JohnsonJohnson & Johnson announces intent to separate its Orthopaedics business

14.10.25EN, Johnson & JohnsonJohnson & Johnson reports Q3 2025 results; raises 2025 sales outlook

13.10.25EN, Johnson & JohnsonJohnson & Johnson Launches INHANCE INTACT™: A Total Shoulder Replacement System Designed for Tissue-Sparing Surgery Providing Day-One Post-Op Mobility

10.10.25EN, Johnson & JohnsonJohnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care*

10.10.25PR NewswireJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress

10.10.25EN, Johnson & JohnsonJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress

08.10.25EN, Johnson & JohnsonU.S. FDA approves SIMPONI® (golimumab) for the treatment of pediatric ulcerative colitis

07.10.25EN, Johnson & JohnsonTREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

07.10.25EN, Johnson & JohnsonIcotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

07.10.25PR NewswireIcotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

07.10.25PR NewswireTREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

07.10.25PR NewswireJohnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

07.10.25EN, Johnson & JohnsonJohnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

29.09.25EN, Johnson & JohnsonU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

29.09.25PR NewswireU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

24.09.25EN, Johnson & JohnsonThe Johnson & Johnson Foundation Announces $5 Million Expanded Investment in Africa Frontline First Catalytic Fund to Strengthen the Community Health Workforce

22.09.25EN, Johnson & JohnsonJohnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR

19.09.25EN, Johnson & JohnsonTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

19.09.25PR NewswireTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

19.09.25EN, Johnson & JohnsonJohnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)

19.09.25EN, Johnson & JohnsonTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

19.09.25PR NewswireTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

17.09.25EN, Johnson & JohnsonIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis

17.09.25PR NewswireIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis

15.09.25EN, Johnson & JohnsonJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting

15.09.25EN, Johnson & JohnsonJohnson & Johnson Announces Launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter in Europe to Transform Treatment of Difficult-to-Cross Calcified Lesions

15.09.25PR NewswireJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting

09.09.25EN, Johnson & JohnsonU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

09.09.25PR NewswireU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

07.09.25EN, Johnson & JohnsonData published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

07.09.25PR NewswireData published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

06.09.25EN, Johnson & JohnsonRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

06.09.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

03.09.25EN, Johnson & JohnsonNew real-world data elevating patient perspectives highlight the need for scientific advancement in maternal fetal immunology at ISUOG 2025

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.